TAL1 Antibody, FITC conjugated is a fluorescently labeled antibody designed for detecting the TAL1 (T-cell acute lymphocytic leukemia 1) transcription factor in biological samples. FITC (fluorescein isothiocyanate) is a green-fluorescent dye covalently linked to the antibody, enabling visualization via fluorescence microscopy, flow cytometry, or immunofluorescence (IF) assays. This conjugation enhances sensitivity and specificity for studying TAL1’s role in hematopoietic regulation, leukemia, and developmental processes .
Western Blotting (WB):
Immunofluorescence (IF) and Immunohistochemistry (IHC-P):
Flow Cytometry (FCM):
Hematopoiesis: TAL1 regulates embryonic blood cell development as a basic helix-loop-helix (bHLH) transcription factor. It heterodimerizes with E-proteins (E2A, HEB) to bind E-box motifs in target genes (e.g., TRIB2, NFKB1) .
Leukemia: Activated TAL1 is implicated in ~60% of T-cell acute lymphoblastic leukemia (T-ALL) cases, driving oncogenic transcription programs .
Recent studies identified two TAL1 isoforms:
TAL1-short: Binds more strongly to E-proteins and occupies DNA sites critical for apoptosis and erythropoiesis .
TAL1-long: Shows weaker E-protein binding and distinct chromatin interactions .
ChIP-seq Validation: FITC-conjugated antibodies enable precise mapping of TAL1 binding sites. For example, TAL1-short shows enriched binding at TRIB2 and NKX3.1 regulatory regions .
Leukemogenesis: TAL1 downregulates tumor suppressors like FBXW7 via miR-223, enhancing leukemia progression .
Cross-Reactivity: Polyclonal antibodies (e.g., Bioss) may recognize multiple epitopes, while monoclonal antibodies (e.g., Santa Cruz, Novus) offer higher specificity .
Isoform Detection: Current antibodies often recognize both TAL1 isoforms, limiting isoform-specific studies. Custom FLAG/GFP-tagged constructs are used in research to distinguish isoforms .